Non-invasive mechanical joint loading as an alternative model for osteoarthritic pain
(2019)
Journal Article
Ter Heegde, F., Luiz, A. P., Santana-Varela, S., Chessell, I. P., Welsh, F., Wood, J. N., & Chenu, C. (2019). Non-invasive mechanical joint loading as an alternative model for osteoarthritic pain. https://doi.org/10.1002/art.40835
Browse
Bidirectional regulation of bone formation by exogenous and osteosarcoma-derived Sema3A (2018)
Journal Article
De Ridder, D., Marino, S., Bishop, R. T., Renema, N., Chenu, C., Heymann, D., & Idris, A. I. (2018). Bidirectional regulation of bone formation by exogenous and osteosarcoma-derived Sema3A. https://doi.org/10.1038/s41598-018-25290-2Semaphorin 3A (Sema3A), a secreted member of the Semaphorin family, increases osteoblast differentiation, stimulates bone formation and enhances fracture healing. Here, we report a previously unknown role of Sema3A in the regulation of ectopic bone f... Read More about Bidirectional regulation of bone formation by exogenous and osteosarcoma-derived Sema3A.
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists (2018)
Journal Article
Mabilleau, G., Pereira, M., & Chenu, C. (2018). Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists. Journal of Endocrinology, 236, R29-R42. https://doi.org/10.1530/JOE-17-0278Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications. In addition, some anti-diabetic therapies for T2DM can have notable detrimental skeletal effect... Read More about Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists.
Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus (2017)
Journal Article
Pereira, M., Gohin, S., Roux, J., Fisher, A., Cleasby, M. E., Mabilleau, G., & Chenu, C. (2017). Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus. Frontiers in Endocrinology, 8(327), https://doi.org/10.3389/fendo.2017.00327Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an increased risk of fractures. Reduced blood supply and bone strength may contribute to this skeletal fragility. We hypothesized that long-term administration of... Read More about Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus.
Prolonging disuse in aged mice amplifies cortical but not trabecular bones’ response to mechanical loading (2017)
Journal Article
De Souza, R., Javaheri, B., Collinson, R. S., Chenu, C., Shefelbine, S., Lee, P. D., & Pitsillides, A. A. (2017). Prolonging disuse in aged mice amplifies cortical but not trabecular bones’ response to mechanical loading
Sclerostin does not play a major role in the pathogenesis of skeletal complications in type 2 diabetes mellitus (2017)
Journal Article
Pereira, M., Gohin, S., Lund, N., Hvid, A., Smitham, P. J., Oddy, M. J., …Chenu, C. (2017). Sclerostin does not play a major role in the pathogenesis of skeletal complications in type 2 diabetes mellitus. Osteoporosis International, 28(1), 309-320. https://doi.org/10.1007/s00198-016-3718-0
Expression of Sulf1 and Sulf2 in cartilage, bone and endochondral fracture healing (2016)
Journal Article
Zaman, G., Staines, K. A., Farquharson, C., Newton, P. T., Dudhia, J., Chenu, C., …Dhoot, G. K. (2016). Expression of Sulf1 and Sulf2 in cartilage, bone and endochondral fracture healing. Histochemistry and Cell Biology, 145(1), 67-79. https://doi.org/10.1007/s00418-015-1365-8
Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice (2015)
Journal Article
Pereira, M., Jeyabalan, J., Jorgensen, C. S., Hopkinson, M., Al-Jazzar, A., Roux, J. P., …Chenu, C. (2015). Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. BONE, 81, 459-67. https://doi.org/10.1016/j.bone.2015.08.006Some anti-diabetic therapies can have adverse effects on bone health and increase fracture risk. In this study, we tested the skeletal effects of chronic administration of two Glucagon-like peptide-1 receptor agonists (GLP-1RA), increasingly used for... Read More about Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice.
Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength (2015)
Journal Article
Lim, S., Marenzana, M., Hopkinson, M., List, E., Kopchick, J., Pereira, M., …Chenu, C. (2015). Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength. Endocrinology, 156(4), 1362-1371. https://doi.org/10.1210/en.2014-1572Patients with acromegaly have a higher prevalence of vertebral fractures despite normal bone mineral density (BMD), suggesting that GH overexpression has adverse effects on skeletal architecture and strength. We used giant bovine GH (bGH) transgenic... Read More about Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength.
Low Dose of Propranolol Does Not Affect Rat Osteotomy Healing and Callus Strength (2014)
Journal Article
Smitham, P., Crossfield, L., Hughes, G., Goodship, A., Blunn, G., & Chenu, C. (2014). Low Dose of Propranolol Does Not Affect Rat Osteotomy Healing and Callus Strength. Journal of Orthopaedic Research, 32(7), 887-893. https://doi.org/10.1002/jor.22619Experimental studies suggest that the β‐blocker propranolol stimulates bone formation but little work has investigated its effect on fracture healing. In this study, we examined if a low dose of propranolol, previously shown to be preventive against... Read More about Low Dose of Propranolol Does Not Affect Rat Osteotomy Healing and Callus Strength.
AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass
Journal Article
Shah, M., Kola, B., Bataveljic, A., Arnett, T. R., Viollet, B., Saxon, L., …Chenu, C. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. BONE, 47(2), 309-319. https://doi.org/10.1016/j.bone.2010.04.596
Neuropeptide Y expression and function during osteoblast differentiation - insights from transthyretin knockout mice
Journal Article
Nunes, A. F., Liz, M. A., Franquinho, F., Teixeira, L., Sousa, V., Chenu, C., …Sousa, M. M. Neuropeptide Y expression and function during osteoblast differentiation - insights from transthyretin knockout mice. FEBS Journal, 277(1), 263-275. https://doi.org/10.1111/j.1742-4658.2009.07482.x
DELETION OF AMP-ACTIVATED PROTEIN KINASE (AMPK)-ALPHA 1 CATALYTIC SUBUNIT IN MICE IMPAIRS THE IN VIVO RESPONSE OF BONES TO HORMONAL CHALLENGES
Journal Article
Shah, M., Viollet, B., Korbonits, M., & Chenu, C. DELETION OF AMP-ACTIVATED PROTEIN KINASE (AMPK)-ALPHA 1 CATALYTIC SUBUNIT IN MICE IMPAIRS THE IN VIVO RESPONSE OF BONES TO HORMONAL CHALLENGES. BONE, 48, S96-S96. https://doi.org/10.1016/j.bone.2011.03.139
DOES THE VASODILATORY ACTION OF PTH HELP ACCOUNT FOR ITS OSTEOGENIC EFFECTS?
Journal Article
Marenzana, M., Chenu, C., Pitsillides, A. A., & Arnett, T. R. DOES THE VASODILATORY ACTION OF PTH HELP ACCOUNT FOR ITS OSTEOGENIC EFFECTS?. BONE, 50, S160-S160. https://doi.org/10.1016/j.bone.2012.02.502
Mice lacking AMP-activated protein kinase alpha 1 catalytic subunit have increased bone remodeling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment.
Journal Article
Jeyabalan, J., Shah, M., Viollet, B., Roux, J. P., Chavassieux, P., Korbonits, M., & Chenu, C. Mice lacking AMP-activated protein kinase alpha 1 catalytic subunit have increased bone remodeling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment. Journal of Endocrinology, 214(3), 349-358. https://doi.org/10.1530/JOE-12-0184
The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing
Journal Article
Jeyabalan, J., Viollet, B., Smitham, P., Ellis, S. A., Zaman, G., Bardin, C., …Chenu, C. The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing. Osteoporosis International, 24(10), 2659. https://doi.org/10.1007/s00198-013-2371-0
THE BONE ANABOLIC EFFECT OF INTERMITTENT PARATHYROID HORMONE IS MODULATED BY VASORELAXATION
Journal Article
Gohin, S., Chenu, C., Pitsillides, A. A., Arnett, T., & Marenzana, M. THE BONE ANABOLIC EFFECT OF INTERMITTENT PARATHYROID HORMONE IS MODULATED BY VASORELAXATION. International Journal of Experimental Pathology, 95(3), A13-A14
Nervous system and bone mechanoregulation
Journal Article
Chenu, C. Nervous system and bone mechanoregulation. Osteoporosis International, 25, S475-+
MECHANOSENSITIVITY OF EMBRYONIC LIMBS: MECHANO-SENSITIVE AND INSENSITIVE PERIODS OF GROWTH, DIFFERENTIAL SENSITIVITY BETWEEN LIMB ELEMENTS, AND THE UNDERPINNING MECHANISMS
Journal Article
Pollard, A. S., McGonnell, I. M., Chenu, C., Farquharson, C., & Pitsillides, A. A. MECHANOSENSITIVITY OF EMBRYONIC LIMBS: MECHANO-SENSITIVE AND INSENSITIVE PERIODS OF GROWTH, DIFFERENTIAL SENSITIVITY BETWEEN LIMB ELEMENTS, AND THE UNDERPINNING MECHANISMS. International Journal of Experimental Pathology, 96(2), A25-A25
The anabolic action of intermittent parathyroid hormone on cortical bone depends partly on its ability to induce nitric oxide-mediated vasorelaxation in BALB/c mice
Journal Article
Gohin, S., Carriero, A., Chenu, C., Pitsillides, A. A., Arnett, T. R., & Marenzana, M. (in press). The anabolic action of intermittent parathyroid hormone on cortical bone depends partly on its ability to induce nitric oxide-mediated vasorelaxation in BALB/c mice. Cell Biochemistry and Function, 34(2), 52-62. https://doi.org/10.1002/cbf.3164
Showing 1 - 20 of 26 results